Elena Giudice

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Sandro Pignata, Giovanni Scambia, Clorinda Schettino et al. · The Lancet Oncology · 2023 · 46 citations

Medicine, Cancer Management, Mito End-3 +7

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair et al. · Nature Communications · 2024 · 35 citations · Full text

Pembrolizumab for advanced cervical cancer: safety and efficacy

Francesca De Felice, Elena Giudice, G. Bolomini et al. · Expert Review of Anticancer Therapy · 2020 · 26 citations

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Lucia Musacchio, Vanda Salutari, Sandro Pignata et al. · International Journal of Gynecological Cancer · 2021 · 22 citations

Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study

Domenica Lorusso, Cláudia Marchetti, Carmine Conte et al. · Gynecologic Oncology · 2020 · 10 citations

Maintenance Treatment, Advanced Ovarian Cancer, Medicine +9